Seneca Valley Virus Past Perspectives And Future...

Oncolytic Seneca Valley Virus: past perspectives and future directions This article covers the Seneca Valley Virus (SVV-001) as a hopeful for an oncolytic treatment of certain cancer types. More specifically those with neuroendocrine properties such as rhabdomyosarcoma, Wilms tumor, glioblastoma, neuroblastoma, and adult small-cell lung cancer. Each of which effect smooth/skeletal muscle cells, kidneys/adrenal glands (mainly in children), astrocytes of the brain, nerve cells of a fetus, and lung cells in adults respectively. The virus was discovered by accident in a contaminated cell culture that contained bovine serum to promote growth. The virus was later discovered to be almost exclusively found in farm animals such as cows and pigs, due to the presence of neutralizing antibodies that were later to only ever have been found in one human sample. Just as important as that, the virus only targets the cells of the above-mentioned cancers/tumors, is a self-replicating RNA virus, and its inability to infect other cells in the body all come together to resu lt in the lysis of these specific cancer cells. These properties alone give great hope for SVV-001 as a treatment for those infected by these diseases, and prompted for more research into its medicinal possibilities. Like every good research study, scientists quickly went into preclinical trials of SVV-001 as an oncolytic treatment. The plan was to test the effectiveness of the virus as a treatment through in vitro test and